Should i sell my astrazeneca shares
AstraZeneca shares buy or sell: potential upside ahead on the back of vaccine momentum. Alejandro Arrieche. For traders News and features Stocks AstraZeneca shares buy or sell: potential upside ahead on the back of vaccine momentum. Rate this article. Share Article. Charts currently unavailable. Grab a coffee. Refresh and try again. Why Capital. Trade Now Trade Now. Simple and intuitive platform. Capital Com is an execution-only service provider.
The material provided on this website is for information purposes only and should not be understood as an investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page.
If you rely on the information on this page then you do so entirely on your own risk. Got a trading idea? Start Trading. Trade Now. Latest video. Oil prices give up gains on Iran nuclear talks by Fitri Wulandari. Indian stock markets look upbeat as Asian indices open firm by Vinu Lal. Still looking for a broker you can trust? Market updates. So what are the near term repercussions of this lost deal?
According to Motley Fool analyst Michael Finarelli, he sees the company treading water in the near term. Two of its major drugs, Nexium and Crestor, are going to be losing patent exclusivity in the next few years, which could hurt the company's bottom line considerably.
That said, Mike does think that the company has some potential blockbusters in the pipeline--though it's never a good idea to blindly bet on an unproven drug. But is that reason enough for current shareholders to abandon ship? On today's "Stock of the Day", Michael says not just yet. While today's drop isn't good news for investors, he says it shouldn't have changed a long term investor's thesis. AstraZeneca has some potential future winners in its pipeline, and investors should stay where they are for now.
Discounted offers are only available to new members. Stock Advisor will renew at the then current list price. Average returns of all recommendations since inception. Although the company had to temporarily pause its late-stage clinical trials of AZD, because of a potential safety issue, everything is back on track now.
AstraZeneca expects to report results from its late-stage study later this year. Most of the company's late-stage programs are targeting additional indications for already-approved drugs. However, AstraZeneca has nine new candidates in late-stage testing, including experimental asthma drugs tezepelumab and PT Investors certainly won't want to overlook AstraZeneca's dividend, which currently yields more than 2.
That's an attractive yield, especially considering the company's overall growth prospects. There is one drawback related to AstraZeneca's dividend: The company doesn't have a great track record of increasing its dividend payout, as some of its rivals do. On the other hand, AstraZeneca shouldn't have any problems keeping the payouts coming, thanks to its strong cash flow. All three of these are great reasons to buy shares of AstraZeneca.
So why would you even want to consider selling the pharma stock -- or not buying it if you don't already own it? I think there's one compelling reason: You want even more. Even though the company should be able to generate strong earnings growth, there's no question that you could find even better growth stocks. And although AstraZeneca's dividend is quite attractive, it's easy to spot stocks that offer much higher dividend yields and have a history of steadily increasing their dividends. My view is that AstraZeneca is a good stock to buy, with its strong current lineup, promising pipeline, and attractive dividend.
But are there even better stocks out there? The answer is unequivocally "yes. Discounted offers are only available to new members. Stock Advisor will renew at the then current list price. Average returns of all recommendations since inception.